Recruiting
Phase 3

Povetacicept vs. Sibeprenlimab

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT07890909

Conditions

Immunoglobulin A Nephropathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Povetacicept

Sibeprenlimab

Study Details

Brief summary:

The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy (IgAN).

Conditions

Immunoglobulin A Nephropathy

Study ID

NCT07890909

Start date

Nov 13, 2026

Status verified date

Nov, 2026

Completion date

Mar 2, 2028

Anticipated

Primary completion date

Dec 12, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Receiving commercial sibeprenlimab 400 mg subcutaneous via PFS for up to (but not exceeding) a maximum of 4 doses of which at least 1 dose is self-injected prior to signing informed consent form
  • Willing and able to comply with scheduled visits, treatment plan including transitioning to povetacicept
  • Biopsy-confirmed primary IgAN
  • 24-hr urine protein/creatinine ratio (UPCR) greater than >0.5 gram (g)/g
  • Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 millilitres per minute (mL/min)/1.73 square meter (m\^2)
  • Able to understand and complete the domains of the Self-Injection Administration Questionnaire (SIAQ)

Key Exclusion Criteria:

  • Use of immunosuppressive or immunomodulatory therapies (except for sibeprenlimab)
  • Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks of the start of screening

Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Povetacicept

Participants previously receiving Sibeprenlimab will self-administer Povetacicept.

Interventions

Povetacicept

Subcutaneous injection administration.

Sibeprenlimab

Subcutaneous injection administration.

Primary outcome measure

  • Change from Baseline in the Self-Injection Administration Questionnaire (SIAQ) Scores at Week 12 After Transitioning to Povetacicept Injection [ Time Frame: Baseline up to Week 12 ]

Central Contacts and Locations

Central contacts

Locations

CTR Oakwater, LLC

Recruiting

Orlando, Florida, United States, 32806

More Information

Sponsor

Vertex Pharmaceuticals Incorporated

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.